Next Article in Journal
Sanguinarine Inhibits Mono- and Dual-Species Biofilm Formation by Candida albicans and Staphylococcus aureus and Induces Mature Hypha Transition of C. albicans
Previous Article in Journal
Production and Characterization of Chitosan–Polyanion Nanoparticles by Polyelectrolyte Complexation Assisted by High-Intensity Sonication for the Modified Release of Methotrexate
Previous Article in Special Issue
A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems
Open AccessArticle

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov

1
Faculty of Management and Economics, Witten/Herdecke University, 58448 Witten, Germany
2
Praxis für Nuklearmedizin, Klinikum der Stadt Ludwigshafen, 67063 Ludwigshafen am Rhein, Germany
3
Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany
4
Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
5
Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany
6
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
*
Authors to whom correspondence should be addressed.
Shared first authorship.
Pharmaceuticals 2020, 13(1), 12; https://doi.org/10.3390/ph13010012
Received: 30 November 2019 / Revised: 16 December 2019 / Accepted: 31 December 2019 / Published: 13 January 2020
The recent development of dedicated prostate-specific membrane antigen (PSMA) targeted radioligands shows the potential to change and improve the diagnosis and therapy of prostate cancer. There is an increasing number of prospective trials to further establish these tracers in the clinical setting. We analyzed data from the ClinicalTrials.gov registry including all listed prospective trials with PSMA-ligands for prostate cancer as of October 2019 concerning the different tracers and study characteristics. We found n = 104 eligible studies with a total of n = 25 different tracers in use: most frequently [68Ga]Ga-PSMA-11 (32%), followed by [18F]DCFPyL (24%) and [177Lu]Lu-PSMA-617 (10%). 85% are single-center, 15% multi-center studies. 95% national and 5% international studies. 34% are phase-II, 24% phase-I, 13% phase-I/-II, 12% phase-II/-III and phase-III and 7% early-phase-I. The primary purpose was classified as diagnostic in 72% of cases and therapeutic in 23% of cases. Most studies were executed in the USA (70%), followed by Canada (13%) and France (6%). This quantitative descriptive registry analysis indicates the rapid and global clinical developments and current status of PSMA-radioligands with emphasis on radiopharmaceutical and organizational aspects. It will be very interesting to see which tracers will prevail in the clinical setting. View Full-Text
Keywords: prostate cancer; PSMA tracer; registry data analysis; ClinicalTrials.gov; theranostics prostate cancer; PSMA tracer; registry data analysis; ClinicalTrials.gov; theranostics
Show Figures

Figure 1

MDPI and ACS Style

Zippel, C.; Ronski, S.C.; Bohnet-Joschko, S.; Giesel, F.L.; Kopka, K. Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. Pharmaceuticals 2020, 13, 12.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop